Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 1708 entries
Sorted by: Best Match Show Resources per page
Pro198Leu missense polymorphism of the glutathione peroxidase 1 gene might be a common genetic predisposition of distal symmetric polyneuropathy and macrovascular disease in Japanese type 2 diabetic patients.

Journal of diabetes investigation

Matsuno S, Sasaki H, Yamasaki H, Yamaoka H, Ogawa K, Nakatani M, Hamanishi T, Doi A, Nakano Y, Wakasaki H, Furuta H, Nishi M, Akamizu T, Nanjo K.
PMID: 24843532
J Diabetes Investig. 2011 Nov 30;2(6):474-82. doi: 10.1111/j.2040-1124.2011.00127.x.

UNLABELLED: Aims/Introduction:  We have previously reported that the Pro198Leu missense polymorphism in the glutathione peroxidase 1 (GPx-1) gene was associated with frequent macrovascular disease (MVD). Our goal was to examine whether the GPx-1 genotype is associated with diabetic neuropathy.MATERIALS...

Cite
Matsuno S, Sasaki H, Yamasaki H, et al. Pro198Leu missense polymorphism of the glutathione peroxidase 1 gene might be a common genetic predisposition of distal symmetric polyneuropathy and macrovascular disease in Japanese type 2 diabetic patients. J Diabetes Investig. 2011;2(6):474-82doi: 10.1111/j.2040-1124.2011.00127.x.
Matsuno, S., Sasaki, H., Yamasaki, H., Yamaoka, H., Ogawa, K., Nakatani, M., Hamanishi, T., Doi, A., Nakano, Y., Wakasaki, H., Furuta, H., Nishi, M., Akamizu, T., & Nanjo, K. (2011). Pro198Leu missense polymorphism of the glutathione peroxidase 1 gene might be a common genetic predisposition of distal symmetric polyneuropathy and macrovascular disease in Japanese type 2 diabetic patients. Journal of diabetes investigation, 2(6), 474-82. https://doi.org/10.1111/j.2040-1124.2011.00127.x
Matsuno, Shohei, et al. "Pro198Leu missense polymorphism of the glutathione peroxidase 1 gene might be a common genetic predisposition of distal symmetric polyneuropathy and macrovascular disease in Japanese type 2 diabetic patients." Journal of diabetes investigation vol. 2,6 (2011): 474-82. doi: https://doi.org/10.1111/j.2040-1124.2011.00127.x
Matsuno S, Sasaki H, Yamasaki H, Yamaoka H, Ogawa K, Nakatani M, Hamanishi T, Doi A, Nakano Y, Wakasaki H, Furuta H, Nishi M, Akamizu T, Nanjo K. Pro198Leu missense polymorphism of the glutathione peroxidase 1 gene might be a common genetic predisposition of distal symmetric polyneuropathy and macrovascular disease in Japanese type 2 diabetic patients. J Diabetes Investig. 2011 Nov 30;2(6):474-82. doi: 10.1111/j.2040-1124.2011.00127.x. PMID: 24843532; PMCID: PMC4014907.
Copy Download .nbib Format: NLM
Safety of exenatide once weekly for 52 weeks in Japanese patients with type 2 diabetes mellitus.

Journal of diabetes investigation

Onishi Y, Koshiyama H, Imaoka T, Haber H, Scism-Bacon J, Boardman MK.
PMID: 24843650
J Diabetes Investig. 2013 Mar 18;4(2):182-9. doi: 10.1111/jdi.12000. Epub 2012 Oct 22.

AIMS/INTRODUCTION: An initial 26-week, randomized, open-label study compared the efficacy and safety of exenatide 10 mcg twice daily with exenatide 2 mg once weekly in Asian patients with type 2 diabetes who experienced inadequate glycemic control with oral antidiabetes...

Cite
Onishi Y, Koshiyama H, Imaoka T, et al. Safety of exenatide once weekly for 52 weeks in Japanese patients with type 2 diabetes mellitus. J Diabetes Investig. 2012;4(2):182-9doi: 10.1111/jdi.12000.
Onishi, Y., Koshiyama, H., Imaoka, T., Haber, H., Scism-Bacon, J., & Boardman, M. K. (2013). Safety of exenatide once weekly for 52 weeks in Japanese patients with type 2 diabetes mellitus. Journal of diabetes investigation, 4(2), 182-9. https://doi.org/10.1111/jdi.12000
Onishi, Yukiko, et al. "Safety of exenatide once weekly for 52 weeks in Japanese patients with type 2 diabetes mellitus." Journal of diabetes investigation vol. 4,2 (2013): 182-9. doi: https://doi.org/10.1111/jdi.12000
Onishi Y, Koshiyama H, Imaoka T, Haber H, Scism-Bacon J, Boardman MK. Safety of exenatide once weekly for 52 weeks in Japanese patients with type 2 diabetes mellitus. J Diabetes Investig. 2013 Mar 18;4(2):182-9. doi: 10.1111/jdi.12000. Epub 2012 Oct 22. PMID: 24843650; PMCID: PMC4019273.
Copy Download .nbib Format: NLM
Clinical and functional characterization of the Pro1198Leu ABCC8 gene mutation associated with permanent neonatal diabetes mellitus.

Journal of diabetes investigation

Takagi T, Furuta H, Miyawaki M, Nagashima K, Shimada T, Doi A, Matsuno S, Tanaka D, Nishi M, Sasaki H, Inagaki N, Yoshikawa N, Nanjo K, Akamizu T.
PMID: 24843665
J Diabetes Investig. 2013 May 06;4(3):269-73. doi: 10.1111/jdi.12049. Epub 2013 Mar 11.

AIMS/INTRODUCTION: The adenosine triphosphate (ATP)-sensitive potassium (KATP) channel is a key component of insulin secretion in pancreatic β-cells. Activating mutations in ABCC8 encoding for the sulfonylurea receptor subunit of the KATP channel have been associated with the development of...

Cite
Takagi T, Furuta H, Miyawaki M, et al. Clinical and functional characterization of the Pro1198Leu ABCC8 gene mutation associated with permanent neonatal diabetes mellitus. J Diabetes Investig. 2013;4(3):269-73doi: 10.1111/jdi.12049.
Takagi, T., Furuta, H., Miyawaki, M., Nagashima, K., Shimada, T., Doi, A., Matsuno, S., Tanaka, D., Nishi, M., Sasaki, H., Inagaki, N., Yoshikawa, N., Nanjo, K., & Akamizu, T. (2013). Clinical and functional characterization of the Pro1198Leu ABCC8 gene mutation associated with permanent neonatal diabetes mellitus. Journal of diabetes investigation, 4(3), 269-73. https://doi.org/10.1111/jdi.12049
Takagi, Tomoyuki, et al. "Clinical and functional characterization of the Pro1198Leu ABCC8 gene mutation associated with permanent neonatal diabetes mellitus." Journal of diabetes investigation vol. 4,3 (2013): 269-73. doi: https://doi.org/10.1111/jdi.12049
Takagi T, Furuta H, Miyawaki M, Nagashima K, Shimada T, Doi A, Matsuno S, Tanaka D, Nishi M, Sasaki H, Inagaki N, Yoshikawa N, Nanjo K, Akamizu T. Clinical and functional characterization of the Pro1198Leu ABCC8 gene mutation associated with permanent neonatal diabetes mellitus. J Diabetes Investig. 2013 May 06;4(3):269-73. doi: 10.1111/jdi.12049. Epub 2013 Mar 11. PMID: 24843665; PMCID: PMC4015663.
Copy Download .nbib Format: NLM
Novel biomarker candidates for the diagnosis of ovarian clear cell carcinoma.

Oncology letters

Kobayashi H, Sugimoto H, Onishi S, Nakano K.
PMID: 26622542
Oncol Lett. 2015 Aug;10(2):612-618. doi: 10.3892/ol.2015.3367. Epub 2015 Jun 11.

Ovarian clear cell carcinoma can arise from endometriosis; however, it is distinct from other types of epithelial ovarian carcinoma in terms of its clinicopathological and molecular features. Cancer antigen 125 lacks the sensitivity and specificity required for accurate clinical...

Cite
Kobayashi H, Sugimoto H, Onishi S, et al. Novel biomarker candidates for the diagnosis of ovarian clear cell carcinoma. Oncol Lett. 2015;10(2):612-618doi: 10.3892/ol.2015.3367.
Kobayashi, H., Sugimoto, H., Onishi, S., & Nakano, K. (2015). Novel biomarker candidates for the diagnosis of ovarian clear cell carcinoma. Oncology letters, 10(2), 612-618. https://doi.org/10.3892/ol.2015.3367
Kobayashi, Hiroshi, et al. "Novel biomarker candidates for the diagnosis of ovarian clear cell carcinoma." Oncology letters vol. 10,2 (2015): 612-618. doi: https://doi.org/10.3892/ol.2015.3367
Kobayashi H, Sugimoto H, Onishi S, Nakano K. Novel biomarker candidates for the diagnosis of ovarian clear cell carcinoma. Oncol Lett. 2015 Aug;10(2):612-618. doi: 10.3892/ol.2015.3367. Epub 2015 Jun 11. PMID: 26622542; PMCID: PMC4509383.
Copy Download .nbib Format: NLM
Cartilage degeneration at symptomatic persistent olecranon physis in adolescent baseball players.

Advances in orthopedics

Enishi T, Matsuura T, Suzue N, Takahashi Y, Sairyo K.
PMID: 25580304
Adv Orthop. 2014;2014:545438. doi: 10.1155/2014/545438. Epub 2014 Dec 18.

Background. Elbow overuse injuries are common in adolescent baseball players, but symptomatic persistent olecranon physis is rare, and its pathogenesis remains unclear. Purpose. To examine the histopathological and imaging findings of advanced persistent olecranon physis. Methods. The olecranon physes...

Cite
Enishi T, Matsuura T, Suzue N, et al. Cartilage degeneration at symptomatic persistent olecranon physis in adolescent baseball players. Adv Orthop. 2014;2014:545438doi: 10.1155/2014/545438.
Enishi, T., Matsuura, T., Suzue, N., Takahashi, Y., & Sairyo, K. (2014). Cartilage degeneration at symptomatic persistent olecranon physis in adolescent baseball players. Advances in orthopedics, 2014545438. https://doi.org/10.1155/2014/545438
Enishi, Tetsuya, et al. "Cartilage degeneration at symptomatic persistent olecranon physis in adolescent baseball players." Advances in orthopedics vol. 2014 (2014): 545438. doi: https://doi.org/10.1155/2014/545438
Enishi T, Matsuura T, Suzue N, Takahashi Y, Sairyo K. Cartilage degeneration at symptomatic persistent olecranon physis in adolescent baseball players. Adv Orthop. 2014;2014:545438. doi: 10.1155/2014/545438. Epub 2014 Dec 18. PMID: 25580304; PMCID: PMC4281472.
Copy Download .nbib Format: NLM
Concern regarding quality and quality of muscle.

Journal of cachexia, sarcopenia and muscle

Saitoh M, Ishida J, Konishi M, Springer J.
PMID: 26674583
J Cachexia Sarcopenia Muscle. 2015 Dec;6(4):394-5. doi: 10.1002/jcsm.12081. Epub 2015 Nov 03.

No abstract available.

Cite
Saitoh M, Ishida J, Konishi M, et al. Concern regarding quality and quality of muscle. J Cachexia Sarcopenia Muscle. 2015;6(4):394-5doi: 10.1002/jcsm.12081.
Saitoh, M., Ishida, J., Konishi, M., & Springer, J. (2015). Concern regarding quality and quality of muscle. Journal of cachexia, sarcopenia and muscle, 6(4), 394-5. https://doi.org/10.1002/jcsm.12081
Saitoh, Masakazu, et al. "Concern regarding quality and quality of muscle." Journal of cachexia, sarcopenia and muscle vol. 6,4 (2015): 394-5. doi: https://doi.org/10.1002/jcsm.12081
Saitoh M, Ishida J, Konishi M, Springer J. Concern regarding quality and quality of muscle. J Cachexia Sarcopenia Muscle. 2015 Dec;6(4):394-5. doi: 10.1002/jcsm.12081. Epub 2015 Nov 03. PMID: 26674583; PMCID: PMC4670750.
Copy Download .nbib Format: NLM
Modeling the budget impact of long-acting injectable paliperidone palmitate in the treatment of schizophrenia in Japan.

ClinicoEconomics and outcomes research : CEOR

Mahlich J, Nishi M, Saito Y.
PMID: 26045674
Clinicoecon Outcomes Res. 2015 May 22;7:267-72. doi: 10.2147/CEOR.S85514. eCollection 2015.

BACKGROUND: The cost of schizophrenia in Japan is high and new long-acting injectable (LAI) antipsychotics might be able to reduce costs by causing a reduction of hospital stays. We aim to estimate budget effects of the introduction of a...

Cite
Mahlich J, Nishi M, Saito Y. Modeling the budget impact of long-acting injectable paliperidone palmitate in the treatment of schizophrenia in Japan. Clinicoecon Outcomes Res. 2015;7:267-72doi: 10.2147/CEOR.S85514.
Mahlich, J., Nishi, M., & Saito, Y. (2015). Modeling the budget impact of long-acting injectable paliperidone palmitate in the treatment of schizophrenia in Japan. ClinicoEconomics and outcomes research : CEOR, 7267-72. https://doi.org/10.2147/CEOR.S85514
Mahlich, Jörg, et al. "Modeling the budget impact of long-acting injectable paliperidone palmitate in the treatment of schizophrenia in Japan." ClinicoEconomics and outcomes research : CEOR vol. 7 (2015): 267-72. doi: https://doi.org/10.2147/CEOR.S85514
Mahlich J, Nishi M, Saito Y. Modeling the budget impact of long-acting injectable paliperidone palmitate in the treatment of schizophrenia in Japan. Clinicoecon Outcomes Res. 2015 May 22;7:267-72. doi: 10.2147/CEOR.S85514. eCollection 2015. PMID: 26045674; PMCID: PMC4447166.
Copy Download .nbib Format: NLM
Hypermetabolism: should cancer types, pathological stages and races be considered in assessing metabolism and could elevated resting energy expenditure be the therapeutic target in patients with advanced cancer?.

Journal of cachexia, sarcopenia and muscle

Ishida J, Konishi M, Saito M, Springer J.
PMID: 26674220
J Cachexia Sarcopenia Muscle. 2015 Dec;6(4):391-2. doi: 10.1002/jcsm.12080. Epub 2015 Oct 27.

No abstract available.

Cite
Ishida J, Konishi M, Saito M, et al. Hypermetabolism: should cancer types, pathological stages and races be considered in assessing metabolism and could elevated resting energy expenditure be the therapeutic target in patients with advanced cancer?. J Cachexia Sarcopenia Muscle. 2015;6(4):391-2doi: 10.1002/jcsm.12080.
Ishida, J., Konishi, M., Saito, M., & Springer, J. (2015). Hypermetabolism: should cancer types, pathological stages and races be considered in assessing metabolism and could elevated resting energy expenditure be the therapeutic target in patients with advanced cancer?. Journal of cachexia, sarcopenia and muscle, 6(4), 391-2. https://doi.org/10.1002/jcsm.12080
Ishida, Junichi, et al. "Hypermetabolism: should cancer types, pathological stages and races be considered in assessing metabolism and could elevated resting energy expenditure be the therapeutic target in patients with advanced cancer?." Journal of cachexia, sarcopenia and muscle vol. 6,4 (2015): 391-2. doi: https://doi.org/10.1002/jcsm.12080
Ishida J, Konishi M, Saito M, Springer J. Hypermetabolism: should cancer types, pathological stages and races be considered in assessing metabolism and could elevated resting energy expenditure be the therapeutic target in patients with advanced cancer?. J Cachexia Sarcopenia Muscle. 2015 Dec;6(4):391-2. doi: 10.1002/jcsm.12080. Epub 2015 Oct 27. PMID: 26674220; PMCID: PMC4670748.
Copy Download .nbib Format: NLM
Anticancer efficacy of a supramolecular complex of a 2-diethylaminoethyl-dextran-MMA graft copolymer and paclitaxel used as an artificial enzyme.

Beilstein journal of nanotechnology

Onishi Y, Eshita Y, Ji RC, Onishi M, Kobayashi T, Mizuno M, Yoshida J, Kubota N.
PMID: 25551057
Beilstein J Nanotechnol. 2014 Dec 01;5:2293-307. doi: 10.3762/bjnano.5.238. eCollection 2014.

The anticancer efficacy of a supramolecular complex that was used as an artificial enzyme against multi-drug-resistant cancer cells was confirmed. A complex of diethylaminoethyl-dextran-methacrylic acid methylester copolymer (DDMC)/paclitaxel (PTX), obtained with PTX as the guest and DDMC as the...

Cite
Onishi Y, Eshita Y, Ji RC, et al. Anticancer efficacy of a supramolecular complex of a 2-diethylaminoethyl-dextran-MMA graft copolymer and paclitaxel used as an artificial enzyme. Beilstein J Nanotechnol. 2014;5:2293-307doi: 10.3762/bjnano.5.238.
Onishi, Y., Eshita, Y., Ji, R. C., Onishi, M., Kobayashi, T., Mizuno, M., Yoshida, J., & Kubota, N. (2014). Anticancer efficacy of a supramolecular complex of a 2-diethylaminoethyl-dextran-MMA graft copolymer and paclitaxel used as an artificial enzyme. Beilstein journal of nanotechnology, 52293-307. https://doi.org/10.3762/bjnano.5.238
Onishi, Yasuhiko, et al. "Anticancer efficacy of a supramolecular complex of a 2-diethylaminoethyl-dextran-MMA graft copolymer and paclitaxel used as an artificial enzyme." Beilstein journal of nanotechnology vol. 5 (2014): 2293-307. doi: https://doi.org/10.3762/bjnano.5.238
Onishi Y, Eshita Y, Ji RC, Onishi M, Kobayashi T, Mizuno M, Yoshida J, Kubota N. Anticancer efficacy of a supramolecular complex of a 2-diethylaminoethyl-dextran-MMA graft copolymer and paclitaxel used as an artificial enzyme. Beilstein J Nanotechnol. 2014 Dec 01;5:2293-307. doi: 10.3762/bjnano.5.238. eCollection 2014. PMID: 25551057; PMCID: PMC4273266.
Copy Download .nbib Format: NLM
Novel mechanism of ghrelin therapy for cachexia.

Journal of cachexia, sarcopenia and muscle

Hatanaka M, Konishi M, Ishida J, Saito M, Springer J.
PMID: 26674390
J Cachexia Sarcopenia Muscle. 2015 Dec;6(4):393. doi: 10.1002/jcsm.12084. Epub 2015 Oct 27.

No abstract available.

Cite
Hatanaka M, Konishi M, Ishida J, et al. Novel mechanism of ghrelin therapy for cachexia. J Cachexia Sarcopenia Muscle. 2015;6(4):393doi: 10.1002/jcsm.12084.
Hatanaka, M., Konishi, M., Ishida, J., Saito, M., & Springer, J. (2015). Novel mechanism of ghrelin therapy for cachexia. Journal of cachexia, sarcopenia and muscle, 6(4), 393. https://doi.org/10.1002/jcsm.12084
Hatanaka, Michiyoshi, et al. "Novel mechanism of ghrelin therapy for cachexia." Journal of cachexia, sarcopenia and muscle vol. 6,4 (2015): 393. doi: https://doi.org/10.1002/jcsm.12084
Hatanaka M, Konishi M, Ishida J, Saito M, Springer J. Novel mechanism of ghrelin therapy for cachexia. J Cachexia Sarcopenia Muscle. 2015 Dec;6(4):393. doi: 10.1002/jcsm.12084. Epub 2015 Oct 27. PMID: 26674390; PMCID: PMC4670749.
Copy Download .nbib Format: NLM
Genetic and environmental influences on motor function: a magnetoencephalographic study of twins.

Frontiers in human neuroscience

Araki T, Hirata M, Sugata H, Yanagisawa T, Onishi M, Watanabe Y, Omura K, Honda C, Hayakawa K, Yorifuji S.
PMID: 24994981
Front Hum Neurosci. 2014 Jun 19;8:455. doi: 10.3389/fnhum.2014.00455. eCollection 2014.

To investigate the effect of genetic and environmental influences on cerebral motor function, we determined similarities and differences of movement-related cortical fields (MRCFs) in middle-aged and elderly monozygotic (MZ) twins. MRCFs were measured using a 160-channel magnetoencephalogram system when...

Cite
Araki T, Hirata M, Sugata H, et al. Genetic and environmental influences on motor function: a magnetoencephalographic study of twins. Front Hum Neurosci. 2014;8:455doi: 10.3389/fnhum.2014.00455.
Araki, T., Hirata, M., Sugata, H., Yanagisawa, T., Onishi, M., Watanabe, Y., Omura, K., Honda, C., Hayakawa, K., & Yorifuji, S. (2014). Genetic and environmental influences on motor function: a magnetoencephalographic study of twins. Frontiers in human neuroscience, 8455. https://doi.org/10.3389/fnhum.2014.00455
Araki, Toshihiko, et al. "Genetic and environmental influences on motor function: a magnetoencephalographic study of twins." Frontiers in human neuroscience vol. 8 (2014): 455. doi: https://doi.org/10.3389/fnhum.2014.00455
Araki T, Hirata M, Sugata H, Yanagisawa T, Onishi M, Watanabe Y, Omura K, Honda C, Hayakawa K, Yorifuji S. Genetic and environmental influences on motor function: a magnetoencephalographic study of twins. Front Hum Neurosci. 2014 Jun 19;8:455. doi: 10.3389/fnhum.2014.00455. eCollection 2014. PMID: 24994981; PMCID: PMC4063293.
Copy Download .nbib Format: NLM
Dynamics of absorption, metabolism, and excretion of 5-aminolevulinic acid in human intestinal Caco-2 cells.

Biochemistry and biophysics reports

Saito K, Fujiwara T, Ota U, Hatta S, Ichikawa S, Kobayashi M, Okitsu Y, Fukuhara N, Onishi Y, Ishizuka M, Tanaka T, Harigae H.
PMID: 28955775
Biochem Biophys Rep. 2017 Jul 13;11:105-111. doi: 10.1016/j.bbrep.2017.07.006. eCollection 2017 Sep.

5-Aminolevulinic acid (ALA) is a precursor for the biosynthesis of porphyrins and heme. Although the oral administration of ALA has been widely applied in clinical settings, the dynamics of its absorption, metabolism, and excretion within enterocytes remain unknown. In...

Cite
Saito K, Fujiwara T, Ota U, et al. Dynamics of absorption, metabolism, and excretion of 5-aminolevulinic acid in human intestinal Caco-2 cells. Biochem Biophys Rep. 2017;11:105-111doi: 10.1016/j.bbrep.2017.07.006.
Saito, K., Fujiwara, T., Ota, U., Hatta, S., Ichikawa, S., Kobayashi, M., Okitsu, Y., Fukuhara, N., Onishi, Y., Ishizuka, M., Tanaka, T., & Harigae, H. (2017). Dynamics of absorption, metabolism, and excretion of 5-aminolevulinic acid in human intestinal Caco-2 cells. Biochemistry and biophysics reports, 11105-111. https://doi.org/10.1016/j.bbrep.2017.07.006
Saito, Kei, et al. "Dynamics of absorption, metabolism, and excretion of 5-aminolevulinic acid in human intestinal Caco-2 cells." Biochemistry and biophysics reports vol. 11 (2017): 105-111. doi: https://doi.org/10.1016/j.bbrep.2017.07.006
Saito K, Fujiwara T, Ota U, Hatta S, Ichikawa S, Kobayashi M, Okitsu Y, Fukuhara N, Onishi Y, Ishizuka M, Tanaka T, Harigae H. Dynamics of absorption, metabolism, and excretion of 5-aminolevulinic acid in human intestinal Caco-2 cells. Biochem Biophys Rep. 2017 Jul 13;11:105-111. doi: 10.1016/j.bbrep.2017.07.006. eCollection 2017 Sep. PMID: 28955775; PMCID: PMC5614713.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 1708 entries